205114-16-5 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
3-Bromo-6-fluoroquinoline is utilized as a key building block for the synthesis of new biologically active compounds. Its unique structure allows for the development of potential drugs to treat a variety of diseases and conditions, making it a valuable asset in the field of medicinal chemistry.
Used in the Synthesis of Other Chemical Compounds and Materials:
Beyond its direct application in drug development, 3-bromo-6-fluoroquinoline also serves as a precursor in the production of other chemical compounds and materials. Its versatility in chemical reactions enables the creation of a diverse range of products with various applications across different industries.
Safety Considerations:
It is essential to handle 3-bromo-6-fluoroquinoline with care due to its potential hazards if not properly managed. Adequate safety measures should be taken during its production, storage, and use to minimize risks and ensure the well-being of those involved in its manipulation.
Check Digit Verification of cas no
The CAS Registry Mumber 205114-16-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,1,1 and 4 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 205114-16:
(8*2)+(7*0)+(6*5)+(5*1)+(4*1)+(3*4)+(2*1)+(1*6)=75
75 % 10 = 5
So 205114-16-5 is a valid CAS Registry Number.
205114-16-5Relevant academic research and scientific papers
QUINOLINYL GLUCAGON RECEPTOR MODULATORS
-
Page/Page column 44-45, (2013/03/26)
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
